Expert Interview
Discussing the recent data from the FLOW trial and the effects of Novo Nordisk's semaglutide on chronic kidney disease in patients with type 2 diabetes.
Ticker(s): NVOInstitution: IU School of Medicine
- Professor of Medicine at Indiana University School of Medicine and Medical Director of DaVita Metro Pointe Dialysis
- Treats 400 patients with CKD who also have Type 2 diabetes per year
- Current research interest in the overlap between nutrition and kidney disease with a particular focus on obesity, omega-3 fatty acids, sudden cardiac death, and diabetic kidney disease; Clinical Interest in general nephrology, dialysis, fluid and electrolyte derangements, and glomerulonephritides.
Roughly how many patients do you treat with CKD who also have Type 2 diabetes per year?
Added By: sara_adminHow are we able to discern whether or not the improvement in CKD related endpoints is due to the mechanism of action of semaglutide, or whether it is due to the weight loss?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for semaglutide in patients with CKD?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
